The Joe Biden administration’s announcement in early May that it would support suspending intellectual property (IP) rights at the World Trade Organization for COVID-19-related vaccines and treatments provoked controversy in the US and abroad.

Advocates argue that waiving Trade-Related Aspects of Intellectual Property Rights (TRIPS) — as South Africa and India proposed late last year — will enable fast, safe, and cheap vaccine manufacturing and distribution to the developing countries suffering most from the pandemic. Opponents contend the waiver will harm future innovation and damage the global IP regime without actually helping those most in need.

Join AEI’s Michael Rosen for a panel discussion on the TRIPS waiver from multiple perspectives, focusing on IP, global public health, supply chains, vaccine diplomacy, and other pressing topics.

Watch the full event here.